News and Press Releases 2006

November 13, 2006
New Data Show ACTOS® (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
November 7, 2006
duetact™ (pioglitazone HCl and glimepiride) Now Available in U.S. Pharmacies
October 20, 2006
Takeda Celebrates U.S. Growth with Grand Opening of New Home Office
October 16, 2006
Takeda to Sponsor The LaSalle Bank Chicago Marathon
September 3, 2006
New Analyses Show ACTOS® (pioglitazone HCl) Reduced Risk of Secondary Stroke by Almost 50 Percent in High-Risk Type 2 Diabetes Patients
July 31, 2006
FDA Approves Duetact™ (pioglitazone HCl and glimepiride) for the Treatment of Type 2 Diabetes
June 12, 2006
New Results from the Landmark PROactive Trial Found That ACTOS® (pioglitazone HCl) Reduced the Occurrence of Major Adverse Cardiovascular Events
June 12, 2006
Cephalon and Takeda Announce Agreement to Co-Promote PROVIGIL® in the United States
June 9, 2006
ACTOS® (pioglitazone HCl) To Be Studied In New Trial Investigating Its Effects On Atherosclerosis In Patients With Type 2 Diabetes
May 22, 2006
New Study Demonstrates that AMITIZA™(lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome with Constipation
May 22, 2006
AMITIZA™(lubiprostone) Shown Effective and Well-Tolerated
May 22, 2006
New Study Finds that Ramelteon Shows Potential for Circadian Phase Shifting
April 25, 2006
AMITIZA™ (lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States
April 3, 2006
Takeda Submits New Drug Application for Extended-Release Type 2 Diabetes Medication, ACTOplus met™(pioglitazone HCl and metformin HCl)
February 22, 2006
Takeda Wins Patent Infringement Litigation against ANDA Filers for Generic ACTOS®
January 31, 2006
Sucampo Obtains FDA Approval for AMITIZATM (lubiprostone) Capsules as Treatment for Chronic Idiopathic Constipation in Adults

Page Top